^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug Class: | CLDN18.2-targeted antibody-drug conjugate |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Published date:
03/08/2023
Excerpt:
Robust tumor regressions were observed in multiple CLDN6+ xenograft models and tumor inhibition lead to markedly enhanced survival of CLDN6+ PDX tumors following treatment with CLDN6-23-ADC….We report the development of a novel antibody-drug conjugate, CLDN6-23-ADC, that selectively targets CLDN6, a potential onco-fetal-antigen which is highly expressed in ovarian and endometrial cancers.
DOI:
https://doi.org/10.1158/1078-0432.CCR-22-2981
